Europe Cancer Diagnostics Market Size & Outlook, 2024-2030
Europe cancer diagnostics market, 2018-2030 (US$M)
Related Markets
Europe cancer diagnostics market highlights
- The Europe cancer diagnostics market generated a revenue of USD 30,795.9 million in 2024.
- The market is expected to grow at a CAGR of 5.7% from 2025 to 2030.
- In terms of segment, public insurance was the largest revenue generating coverage in 2024.
- Public insurance is the most lucrative coverage segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2025 to 2030.
Europe data book summary
| Market revenue in 2024 | USD 30,795.9 million |
| Market revenue in 2030 | USD 42,488.4 million |
| Growth rate | 5.7% (CAGR from 2025 to 2030) |
| Largest segment | Public insurance |
| Fastest growing segment | Public insurance |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Public insurance, Private |
| Key market players worldwide | Abbott Laboratories, Roche Holding AG, GE HealthCare Technologies Inc Common Stock, Qiagen NV, Becton Dickinson & Co, Koninklijke Philips NV, Siemens Healthineers AG ADR, Hologic Inc, Thermo Fisher Scientific Inc, Illumina Inc |
Other key industry trends
- In terms of revenue, Europe region accounted for 28.1% of the global cancer diagnostics market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 31,420.2 million by 2030.
Public insurance was the largest segment with a revenue share of 77.64% in 2024. Horizon Databook has segmented the Europe cancer diagnostics market based on public insurance, private covering the revenue growth of each sub-segment from 2018 to 2030.
Europe accounts for a considerable revenue share of the cancer diagnostics market due to the presence of developed economies, such as Germany, Spain, the UK, France, and Italy. These countries have advanced infrastructure, which is anticipated to significantly boost clinical research prospects in the region.
Moreover, the market growth can be attributed to a growing biotechnology industry and rising investments in genomic sequencing in countries such as the UK & Germany. In February 2022, Invitae introduced its LiquidPlex Dx and FusionPlex Dx Cancer Testing Kit with the CE Mark for use in Europe.
Neuroblastoma predominantly affects toddlers and young children, with approximately 1,500 new cases reported annually in the EU. This malignant tumor targets the peripheral nervous system, with around 50% of patients classified as high-risk cases. Recurrences are common, and conventional treatments often prove ineffective for young patients.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Diagnostics Market Scope
Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe cancer diagnostics market size, by country, 2018-2030 (US$M)
Europe Cancer Diagnostics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
